Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 8/20 | 0.56 |
| ▸ | SELP | P16109 | 1/20 | 0.41 |
| ▸ | ALB | P02768 | 2/20 | 0.39 |
| ▸ | FOLH1 | Q04609 | 4/20 | 0.37 |
| ▸ | NOD1 | Q9Y239 | 3/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
| ▸ | THPO | P40225 | 1/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | BLM | P54132 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19261666 | 0.90 | GLP1R (0.53) | GLP1RALBFOLH1SMN1; SMN2KDM4E | |
| SCHEMBL13184655 | 0.90 | GLP1R (0.53) | GLP1RALBFOLH1NOD1SMN1; SMN2 | |
| SCHEMBL71066 | 0.90 | GLP1R (0.58) | GLP1RSELPNOD1SMN1; SMN2 | |
| SCHEMBL24486689 | 0.90 | GLP1R (0.53) | GLP1RSELPALBFOLH1NOD1 | |
| SCHEMBL15002721 | 0.89 | GLP1R (0.57) | GLP1RSELPNOD1 | |
| SCHEMBL17131127 | 0.89 | GLP1R (0.54) | GLP1RSELPFOLH1NOD1 | |
| SCHEMBL71225 | 0.88 | GLP1R (0.56) | GLP1RSELPFOLH1NOD1 | |
| SCHEMBL25546631 | 0.88 | GLP1R (0.52) | GLP1RALBFOLH1SMN1; SMN2KDM4E | |
| SCHEMBL17424474 | 0.88 | GLP1R (0.53) | GLP1RSELPSMN1; SMN2 | |
| SCHEMBL24665447 | 0.87 | GLP1R (0.51) | GLP1RSELPALBFOLH1NOD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130143798-A1 | NOVEL GLUCAGON ANALOGUES | NOVO NORDISK A/S (DK) | 2013-06-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130143798-A1 | NOVEL GLUCAGON ANALOGUES | GLP1R, GCG, IAPP | GLP1R 1/4885SELP 2939/4885ALB 1619/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.